For its second fiscal quarter (ending June 30), Halozyme Therapeutics Inc (NASDAQ: HALO) has reported a 28% increase in E.P.S. from $0.57 a year ago to $0.73 in the current quarter. However, this performance was $-0.06 short of the consensus estimate of $0.79. For the latest four quarters through June 30, E.P.S. were $2.62 versus $1.74 for the same period a year ago — an increase of 51%.
Recent Price Action
Halozyme Therapeutics Inc (NASDAQ: HALO) stock closed at $51.94 on 8/6/24 after a slight decline of -0.3%. Trading volume in this decline was normal. The stock has declined -6.4% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, HALO is expected to continue to be a major Value Builder.
Halozyme Therapeutics has a current Value Trend Rating of A (Highest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Halozyme Therapeutics has a very high Power Rating of 87 and a very high Appreciation Score of 98, triggering the Highest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment